Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc. | Magrolimab in Combination With Nab-Paclitaxel | Metastatic triple-negative breast cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Hepcludex (Bulevirtide) - (MYR204) | Hepatitis delta virus (HDV) | Phase 2b | Trial Completed | Subcutaneous | Antiviral |
| Gilead Sciences Inc. | Magrolimab | Head and neck squamous cell carcinoma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Relapsed/Refractory Multiple Myeloma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Sacituzumab Govitecan + Pembrolizumab - (EVOKE-02) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Gilead Sciences Inc. | Sacituzumab govitecan (SG) | Metastatic castration resistant prostate cancer (mCRPC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Gilead Sciences Inc. | Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221) | Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel - (EVOKE-01) | Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
